Cannabinoid Pathways Amplify Mitragynine's Effect Against Neuropathic Pain

Why it matters

Millions of kratom users also use cannabis, and this study reveals why that combination may be especially effective for neuropathic pain — cannabinoid receptors are integral to mitragynine's analgesic mechanism.

The big picture

These findings suggest that combining kratom and cannabis may produce synergistic neuropathic pain relief, potentially informing future combination therapies for conditions like chemotherapy-induced peripheral neuropathy.

Key findings

• • Cannabinoid receptor deletion (CB1/CB2 knockout) significantly reduced mitragynine's effectiveness against oxaliplatin-induced neuropathic pain
• • CB1, CB2, and TRPV1 pharmacological blockade completely eliminated mitragynine's anti-neuropathic effects
• • Cannabinoid involvement was selective to neuropathic pain — not inflammatory formalin-induced pain
• • Mitragynine prevented oxaliplatin-induced disruption of the spinal cord endocannabinoid lipidome

What they say

Preclinical study using wildtype and cannabinoid receptor knockout mice with pharmacological antagonists; conducted at Temple University and Indiana University, published in Life Sciences (2023).

Bottom line

Mitragynine's ability to relieve chemotherapy-induced neuropathic pain depends significantly on cannabinoid receptor signaling, explaining why kratom-cannabis co-use may enhance pain relief.